From CKD to Precision Nephrology: Five Takeaways from ASN Kidney Week 2026
Kidney disease is entering a new era of scientific and therapeutic innovation. At ASN Kidney Week 2026, the breadth of research ranged from CKD and the cardiovascular-kidney-metabolic axis to IgA nephropathy and other glomerular diseases, ADPKD, dialysis and transplantation, including xenotransplantation. Acute kidney injury and the growing role of biomarkers and precision medicine were also important themes.
For biotech and pharmaceutical companies developing new renal therapies, five themes stood out.
1. Nephrology is becoming more precise
The shift towards more targeted approaches was evident across the programme, with dedicated research in IgA nephropathy, membranous nephropathy, ADPKD, C3 glomerulonephropathy and other glomerular diseases.
The growing focus on immunological, genetic and molecular disease characterization reflects a broader transition from traditional diagnostic categories towards mechanism-based treatment.
For drug developers, this puts greater emphasis on understanding disease biology and defining the right patient population early.
2. IgA nephropathy continues to drive innovation
IgANwas a prominent area of research, with three important trials included in the opening plenary session and continued focus on emerging approaches such as BAFF/APRIL-directed therapies.
However, innovation is extending beyond IgAN to FSGS, membranous nephropathy, C3 glomerulopathy and other immune-mediated kidney diseases.
Important questions include how therapies should be combined or sequenced, which patient subgroups are most likely to benefit from each approach and how those populations can be identified.
Recent experience in IgAN may help inform development strategies for other glomerular diseases, fostering broader stakeholder consensus and regulatory alignment on meaningful endpoints, optimal eGFR and proteinuria monitoring periods, and the validation needed to support their use as indicators of sustained clinical benefit.
Innovative trial designs, including adaptive, biomarker-enriched and platform approaches, may improve efficiency and evidence generation in rare and heterogeneous populations.
As treatment options expand, sponsors face a more complex development landscape, increasing the importance of patient selection, meaningful endpoints, treatment positioning and differentiation.
3. Kidney and cardiometabolic disease are increasingly interconnected
The cardiovascular-kidney-metabolic axis had dedicated programming at Kidney Week, alongside discussion of GLP-1 receptor agonists, obesity and cardiovascular risk in CKD.
For clinical development, the implications extend beyond kidney function alone. Sponsors increasingly need to consider kidney disease within the wider cardiovascular and metabolic profile of the patient.
4. Biomarkers can help drive more precise development
Kidney Week included dedicated research on CKD biomarkers, outcomes and precision care.
Across glomerular diseases, AKI and transplantation, biomarkers are increasingly being explored to identify relevant patient subgroups, confirm target engagement, monitor response and detect injury or recurrence earlier. This includes moving beyond traditional measures such as proteinuria, albuminuria and eGFR to incorporate disease-specific autoantibodies, complement markers, urinary injury markers, genetic and molecular signatures, and multi-omics approaches that may provide earlier and more disease-specific insights.
For sponsors, biomarker strategy, patient stratification, endpoints and statistical planning are increasingly important considerations when designing programmes capable of demonstrating meaningful clinical benefit.
5. The focus is shifting from discovery to implementation
With multiple therapeutic approaches emerging, an important challenge is how new treatments could fit within an evolving standard of care. Kidney Week discussions addressed treatment sequencing, combination use and the implementation of established and emerging therapies across kidney diseases.
For biotech and pharmaceutical companies, generating strong efficacy and safety evidence remains essential, but positioning a therapy within an increasingly complex treatment landscape is also becoming an important development consideration.
Moving towards precision nephrology
The key takeaway from ASN Kidney Week 2026 is clear: renal drug development is becoming more targeted, more interconnected and more therapeutically diverse.
It is also becoming more patient-centered, with increasing attention to symptoms, physical function, treatment burden and quality of life alongside traditional renal outcomes.
For sponsors, this means bringing together disease biology, patient selection, biomarkers, endpoints, clinical operations and evidence strategy earlier in development.
For Emerald Clinical, it reinforces the value of combining deep renal expertise with clinical and operational strategy to help biotech and pharma translate promising kidney science into meaningful evidence.
The opportunity in renal research is accelerating. The challenge now is building development programmes capable of keeping pace.